MedTrace Logo

Safety and Efficacy of Drug Combinations Against Trichuris Trichiura

NCT01050452 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2010-01-15

No results posted yet for this study

Summary

This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of albendazole (ALB), mebendazole (MBD) and ivermectin (IVM) separately, and ALB and MBD each in combination with IVM in the treatment of Trichuris trichiura in children aged 5-14 years.

Conditions

  • Parasitic Diseases

Interventions

DRUG

albendazole

albendazole (400 mg on dose)

DRUG

mebendazole

mebendazole (500 mg one dose)

DRUG

ivermectin

ivermectin (200 microgram/kg body weight)

DRUG

albendazole + ivermectin

albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)

DRUG

mebendazole + ivermectin

mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)

Sponsors & Collaborators

  • DBL -Institute for Health Research and Development

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01050452 on ClinicalTrials.gov